PHARMACOLOGICAL MODULATION OF THE METABOLIC–REPRODUCTIVE AXIS IN POLYCYSTIC OVARY SYNDROME: A PHENOTYPE-ORIENTED REVIEW OF INSULIN SENSITIZATION, WEIGHT MANAGEMENT, AND OVULATION INDUCTION

Authors

Keywords:

polycystic ovary syndrome, insulin resistance, metformin, GLP-1 receptor agonists, letrozole, clomiphene citrate, obesity, hyperandrogenism, ovulation, infertility, pharmacotherapy.

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder in which insulin resistance, hyperinsulinemia, hyperandrogenism, adiposity, dyslipidemia, abnormal folliculogenesis, and anovulation interact through multiple pathophysiological pathways. This heterogeneity limits the effectiveness of a uniform pharmacological approach and supports treatment selection according to the dominant metabolic and reproductive phenotype.

Objective: To critically review contemporary pharmacological strategies targeting the metabolic–reproductive axis in PCOS and to evaluate the roles of metformin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), anti-obesity agents, inositols, letrozole, clomiphene citrate, and gonadotropin-based therapy in relation to insulin resistance, androgen excess, ovulatory dysfunction, and fertility outcomes.

Materials and Methods: A focused narrative review of contemporary international guidelines, systematic reviews, meta-analyses, randomized controlled trials, and major mechanistic studies was undertaken. Priority was given to evidence published or updated between 2023 and 2026, together with selected foundational studies describing the metabolic and reproductive pathophysiology of PCOS. The analysis focused on drug mechanism, metabolic effects, reproductive efficacy, safety, and clinical positioning according to PCOS phenotype.

Results: Metformin remains the best-established insulin-sensitizing pharmacological option for metabolic manifestations of PCOS and produces modest improvements in insulin resistance, fasting glucose, body mass index, and selected reproductive outcomes, particularly when metabolic dysfunction is prominent. Letrozole is the preferred first-line pharmacological agent for ovulation induction in women with anovulatory infertility and no additional infertility factors. Clomiphene citrate remains an effective alternative, while its combination with metformin may be advantageous in selected women. GLP-1 RAs demonstrate clinically relevant weight reduction in women with PCOS and overweight or obesity, but evidence for direct improvement in ovulation, pregnancy, and live birth remains insufficient. Inositol may improve selected metabolic parameters, but current evidence does not support its use as an established fertility therapy. Gonadotropins retain an important second-line role when oral ovulation-induction therapy is unsuccessful.

Conclusion: Pharmacotherapy of PCOS should be based on metabolic–reproductive phenotyping rather than on ovarian morphology alone. Metformin is most appropriately positioned as a metabolic modifier, letrozole as first-line ovulation induction, and GLP-1 RAs as emerging agents for weight-centred metabolic management in appropriately selected women. Future trials should determine whether correction of insulin resistance before conception translates into sustained improvements in ovulation, pregnancy, live birth, and long-term maternal metabolic outcomes.

 

References

1.Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767–793. doi:10.1016/j.fertnstert.2023.07.025.

2.Christ JP, Cedars MI. Current guidelines for diagnosing PCOS. Diagnostics (Basel). 2023;13(6):1113. doi:10.3390/diagnostics13061113.

3.Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. doi:10.1038/nrdp.2016.57.

4.Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284.

5.Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520.

6.Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JSE, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487–525.

7.Yun BH, Seo SK, Maher JY, Dowlut-McElroy T, Gomez-Lobo V. Prepregnancy insulin resistance and fertility and pregnancy outcomes in women with polycystic ovarian syndrome. Obstet Gynecol. 2026. doi:10.1097/AOG.0000000000006318.

8.Melin J, Forslund M, Alesi S, et al. The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Eur J Endocrinol. 2023;189(2)–S64. doi:10.1093/ejendo/lvad098.

9.Goldberg A, Graca S, Liu J, et al. Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obes Rev. 2024;25(5). doi:10.1111/obr.13704.

10.Forslund M, Wändell P, Forsberg L, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2026;194(3)–S39. doi:10.1093/ejendo/lvag033.

11.Franik S, Le QK, Kremer JAM, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022;9. doi:10.1002/14651858.CD010287.pub4.

12.Fitz V, Graca S, Mahalingaiah S, et al. Inositol for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. J Clin Endocrinol Metab. 2024;109(6):1630–1655. doi:10.1210/clinem/dgad762.

13.Bahri Khomami M, Shorakae S, Hashemi S, et al. Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nat Commun. 2024;15:5591. doi:10.1038/s41467-024-49749-1.

14.Bahri Khomami M, Hashemi S, Shorakae S, et al. Systematic review and meta-analysis of birth outcomes in women with polycystic ovary syndrome. Nat Commun. 2024;15:5592. doi:10.1038/s41467-024-49752-6.

15.Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–637.

16.Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95(3):1073–1079.e11.

17.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

18.International PCOS Network. International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University; 2023.

Published

2026-10-08